Nightstar Marks Latest Foreign Biotech To File US IPO
Nightstar Therapeutics Ltd., a venture-backed, U.K. gene therapy company developing treatments for rare retinal diseases that could lead to blindness, filed an $86 million initial public offering on Thursday, marking the...To view the full article, register now.
Already a subscriber? Click here to view full article